RxDoctor Payments Data

Stephen Robinson, MD

Family Medicine · Salisbury, MDNPI 1295077519

Payments from drug & device makers

$662in general payments, 2019–2025

Across 25 payments — averaging $26.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$202
  • AbbVie$123
  • GSK$55
  • Astellas Pharma US Inc$44
  • Abbott$42
  • AstraZeneca$35
  • plus $160 from 8 others

What the payments were for

  • Food & beverage$65098%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$662 in reported general payments places this provider in the 60th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$39,764
Medicare patients
581
Services billed
958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide107$108,581
OzempicSemaglutide73$94,147
EliquisApixaban94$84,362
JardianceEmpagliflozin64$81,498
RybelsusSemaglutide29$47,908
XareltoRivaroxaban37$40,866
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$21,159
EntrestoSacubitril/Valsartan18$18,326
MounjaroTirzepatide16$15,592
Incruse ElliptaUmeclidinium Bromide37$15,287
FarxigaDapagliflozin Propanediol20$14,823
RayaldeeCalcifediol11$12,877
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$8,308
SymbicortBudesonide/Formoterol Fumarate26$8,261
KerendiaFinerenone13$8,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$202$142,056102 claims
Lilly USA, LLCTrulicity, Mounjaro$12$124,173123 claims
PfizerEliquis$35$84,36294 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$55$43,14387 claims
AstraZenecaFarxiga, Symbicort$35$23,08446 claims
MerckDulera$12$6,30515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →